<DOC>
	<DOCNO>NCT00956644</DOCNO>
	<brief_summary>Primary Objective : - To demonstrate antihypertensive efficacy fix combination irbesartan/amlodipine 150/5 mg superior amlodipine 5 mg monotherapy lower systolic blood pressure ( SBP ) measure home blood pressure measurement ( HBPM ) 5 week treatment ( W5 ) Secondary Objective : - To compare antihypertensive efficacy fix combination irbesartan/amlodipine 150/5 mg amlodipine 5 mg monotherapy 5 week treatment ( W5 ) - To compare antihypertensive efficacy fix combination therapy irbesartan/amlodipine 150/10 mg amlodipine 10 mg monotherapy end treatment ( W10 ) - To examine treatment group change week 5 week 10 SBP diastolic blood pressure ( DBP ) assess HBPM office blood pressure measurement ( OBPM ) - To determine incidence severity adverse event</brief_summary>
	<brief_title>Irbesartan/Amlodipine Hypertensive Patients Uncontrolled Amlodipine 5 mg Monotherapy</brief_title>
	<detailed_description />
	<mesh_term>Irbesartan</mesh_term>
	<mesh_term>Amlodipine</mesh_term>
	<criteria>Inclusion criterion : Established essential hypertension Treated amlodipine 5 mg monotherapy least 4 week With uncontrolled BP define mean SBP = &gt; 145 mmHg assess OBPM Signed write inform consent obtain prior inclusion study Randomisation Criteria : Mean SBP = &gt; 135 mmHg assess HBPM Good compliance HBPM protocol define least 12 correct measurement perform last 6 day first period measurement Creatinine clearance = &gt; 30 ml/min , determine Cockroft formula Exclusion criterion : Mean SBP = &gt; 180 mm Hg and/or mean DBP = &gt; 110 mm Hg measure doctor 's office Visit 1 Known suspect cause secondary hypertension Patients bilateral artery stenosis , renal artery stenosis solitary kidney , renal transplant one functioning kidney Know contraindications hypersensitivity either amlodipine irbesartan combination history angioedema related administration angiotensin II receptor antagonist combination drug use Known type 1 diabetes Know severe hepatic impairment alanine aminotransferase ( ALT ) aspartate aminotransferase ( AST ) &gt; 5 time upper limit normal history hepatic encephalopathy , esophageal varix , portocaval shunt Known severe renal impairment ( creatinine clearance &lt; 30 ml/mn ) Concomitant use antihypertensive treatment Administration investigational drug within 30 day inclusion Inability obtain valid automatic BP measurement record Presence severe medical psychological condition , opinion investigator , indicate participation study best interest patient Presence condition ( e.g . : geographical , social , etc ) would restrict limit patient participation duration study Pregnant breast feed woman Women childbearing potential unable unwilling use acceptable method avoid pregnancy entire study period The information intend contain consideration relevant patient 's potential participation clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2010</verification_date>
</DOC>